Capricor Therapeutics Inc earnings per share and revenue
On Nov 10, 2025, CAPR reported earnings of -0.54 USD per share (EPS) for Q3 25, beating the estimate of -0.55 USD, resulting in a 3.31% surprise. Revenue reached --, compared to an expected 544.00 thousand, with a -100.00% difference. The market reacted with a +11.51% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 analysts forecast an EPS of -0.55 USD, with revenue projected to reach -- USD, implying an increase of 1.85% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
High Tide Inc. Common Shares
Report Date
Jan 29, 2026 For Q4 25
Estimate
$0.00
Actual
$0.01
Surprise
0.00%
Abbott Laboratories
Report Date
Jan 22, 2026 For Q4 25
Estimate
$1.51
Actual
$1.50
Surprise
-0.75%
Stryker Corporation
Report Date
Jan 29, 2026 For Q4 25
Estimate
$4.43
Actual
$4.47
Surprise
+0.69%
ResMed Inc.
Report Date
Jan 29, 2026 For Q2 26
Estimate
$2.75
Actual
$2.81
Surprise
+2.15%
FAQ
What were Capricor Therapeutics Inc's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Capricor Therapeutics Inc reported EPS of -$0.54, beating estimates by 3.31%, and revenue of $0.00, -100% below expectations.
How did the market react to Capricor Therapeutics Inc's Q3 2025 earnings?
The stock price moved up 11.51%, changed from $5.56 before the earnings release to $6.20 the day after.
When is Capricor Therapeutics Inc expected to report next?
The next earning report is scheduled for Mar 17, 2026.
What are the forecasts for Capricor Therapeutics Inc's next earnings report?
Based on 12
analysts, Capricor Therapeutics Inc is expected to report EPS of -$0.55 and revenue of -- for Q4 2025.